-
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk ...
International audience -
Antithymocyte globulins and chronic graft-vs-host disease after myeloablative...
International audience -
Risk factors associated with increased nonrelapse mortality and with poor ove...
International audience
